Federica Riu
YOU?
Author Swipe
View article: The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease Open
A novel potential treatment for peripheral arterial disease (PAD) is described. Inhibition of SRPK1, or knockout in monocytes, induces angiogenesis by preventing splicing to antiangiogenic VEGF (VEGF-A 165 b) in patients and animal models.…
View article: The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease
The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease Open
Introduction In peripheral arterial disease (PAD) anti-angiogenic VEGF-A 165 b isoform overexpression in monocytes contributes to impaired collateralisation. Serine-arginine protein-kinase-1 (SRPK1) regulates VEGF splicing. To determine wh…
View article: Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy
Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy Open
VEGF-A165a splicing is induced by hyperglycemia through PKC-mediated activation of SRPK1 in RPE cells, increasing their permeability and angiogenic capability. SRPK1 inhibitors can be given as eye drops to reduce retinal permeability and e…
View article: Enhanced notch signaling modulates unproductive revascularization in response to nitric oxide‐angiopoietin signaling in a mouse model of peripheral ischemia
Enhanced notch signaling modulates unproductive revascularization in response to nitric oxide‐angiopoietin signaling in a mouse model of peripheral ischemia Open
Introduction Arteriolargenesis can be induced by concomitant stimulation of nitric Oxide (NO)‐Angiopoietin receptor (Tie)‐Vascular Endothelial Growth Factor (VEGF) signaling in the rat mesentery angiogenesis assay. We hypothesized that the…